Pharmaceutical Grade CAS 51352-87-5 Nootropics Prl-8-53 Powder Prl-8-53

PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine(Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.

PRL-8-53 (chemical name Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate) is a synthetic nootropic compound discovered in 1972 and patented in 1975 by the late Dr. Nikolaus Hansl, a neuropharmacologist at Creighton University in Omaha, Nebraska. Preliminary animal tests indicated that the compound was both safe and significantly nootropic, boosting avoidance learning in rodents with no adverse effects. But the real interest in PRL-8-53 was sparked by a 1978 study on human volunteers, which showed that a single dose of the compound could improve word retention scores by more than 200%. 
 

PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine (Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl atCreighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.

PRL-8-53 is relatively non-toxic, with an oral LD50 in mice of 860 mg/kg, 

giving the drug a high therapeutic index. Doses above 8 mg/kg have brief hypotensiveeffects in the canine.High doses depress motor activity in the rat and mouse, with the ED50 for a 50% reduction in motor activity of mice at 160 mg/kg.

1. Enhance cognition and memory formation 

2. Anxiolytic properties

3. Anti-depressive effect 

4. Treatment of Alzheimer's and Parkinson's disease

5. Increase coordination

6. Improves mood

7. Help fight fatigue 

8. Prevent oxidation within the brain

9. Treat alcohol related brain damage

10. Prevent caffein withdrawal symptoms